US Tevimbra Approval Validates BeiGene’s Asia-Heavy Global Trial Approach

Major Milestone For R&D Strategy

 
• By Dexter Jie Yan

BeiGene's first US approval for Tevimbra (tislelizumab), based on an Asia-heavy global study, is expected to pave the way for the biopharma to win two more approvals within 2024.

Asia strategy
BeiGene adopts a “more global approach to clinical trials” for the devleopment of its PD-1 inhibitor. • Source: Shutterstock

More from China

More from Focus On Asia